Hookworm remains one of the most common parasitic infections on earth, quietly draining iron and protein from hundreds of millions of people, particularly children and pregnant women in regions with poor sanitation. Albendazole, sold under the brand name Albenza in the United States, is the medicine most consistently recommended for treating it. This article lays out what the clinical evidence actually demonstrates about its effectiveness, how it is dosed in practice, and what a patient can realistically expect during and after treatment.

What Hookworm Does and Why Treatment Matters

Human hookworm disease is caused mainly by two species, Necator americanus and Ancylostoma duodenale. Larvae typically penetrate the skin, usually through bare feet in soil contaminated with human waste, travel through the bloodstream to the lungs, and are coughed up and swallowed, settling finally in the small intestine. There, adult worms attach to the intestinal wall and feed on blood, sometimes for years. The consequence is rarely dramatic in the short term, but the cumulative toll — iron-deficiency anemia, protein loss, impaired growth in children, and complications in pregnancy — is well documented in field studies from Africa, Asia, and Latin America. The body was not designed to tolerate a parasite feeding on it indefinitely, and treating the infection is simply good stewardship of one's own health and one's family's.

Diagnosis is usually made by examining a stool sample under a microscope for hookworm eggs, often using a standardized technique called Kato-Katz thick smear, which also allows researchers and clinicians to estimate the intensity of infection by counting eggs per gram of stool.

How Albendazole Kills the Worm

Albendazole belongs to a class of drugs called benzimidazoles. Its mechanism is well characterized at the biochemical level: it binds selectively to a structural protein called beta-tubulin inside the parasite's cells, preventing the normal assembly of microtubules. Microtubules are essential scaffolding structures that the worm's intestinal cells rely on to absorb glucose. Without them, the worm can no longer take up sugar, its glycogen reserves are depleted, and it gradually starves and dies over the course of several days. This selectivity for parasite tubulin over human tubulin, discovered through pharmacological research in the 1970s and refined since, is what makes the drug tolerable for the patient while being lethal to the worm. It is a reminder that some of the most useful tools in medicine were derived from careful, patient study of ordinary biology rather than novel invention — the compound's antecedents trace back to a broader family of anti-parasitic chemicals investigated originally for veterinary and agricultural use.

The Evidence Behind Albendazole for Hookworm

Albendazole's role against hookworm is supported by decades of field trials rather than a single landmark study, which is itself a strength: the drug has been tested across many countries, worm burdens, and age groups. One of the most cited analyses is a 2008 systematic review and meta-analysis published in JAMA by Jennifer Keiser and Jürg Utzinger, then at the Swiss Tropical Institute, which pooled data from dozens of trials on soil-transmitted helminths. That analysis found a single 400 mg dose of albendazole produced a cure rate (complete clearance of eggs from stool) of roughly 80 percent against hookworm, alongside substantial reductions in egg counts even among those not fully cured — meaning worm burden, and therefore blood loss, dropped sharply even when the infection was not completely eliminated. Cure rates against Ascaris roundworm in the same analysis were considerably higher, above 95 percent, while single-dose albendazole performed poorly against whipworm (Trichuris trichiura), underscoring that these are related but distinct infections requiring different expectations.

A later meta-analysis, published in the BMJ in 2017 by Michael Moser and colleagues, revisited efficacy across newer trials conducted as mass deworming programs expanded globally through the 2000s and 2010s. It found albendazole's cure rates against hookworm remained good, though egg reduction rates for some soil-transmitted helminths showed modest declines over time in certain regions, a trend researchers attribute partly to the biology of repeated, population-wide dosing and which is monitored closely by the World Health Organization as part of ongoing surveillance for reduced drug sensitivity. This is not evidence of the drug failing broadly; it is evidence that resistance monitoring, like any responsible long-term public health effort, requires ongoing vigilance rather than complacency.

It is worth being precise about regulatory status. In the United States, albendazole's FDA-approved indications are neurocysticercosis and hydatid (echinococcal) disease. Its use for hookworm and other intestinal soil-transmitted helminths in the U.S. is supported by World Health Organization guidance, CDC recommendations, and extensive international trial data, and is standard practice among clinicians treating these infections, but it is technically an off-label use domestically. This is a common and well-accepted situation in infectious disease medicine, and it does not reflect uncertainty about whether the drug works — the international evidence for that is strong — but reflects how U.S. drug labeling has historically prioritized indications more common in domestic practice.

Dosing in Practice

For uncomplicated hookworm infection in adults and children over two years old, the standard regimen recommended by the World Health Organization is a single oral dose of 400 mg, taken with or without food, though absorption is somewhat improved with a fatty meal.

Pregnancy deserves specific mention. Animal studies have shown embryotoxic and teratogenic effects at high doses, and albendazole is generally avoided in the first trimester. The World Health Organization has, in some heavily endemic settings, supported treatment after the first trimester because untreated hookworm-related anemia carries its own real risks to mother and child. This is precisely the kind of judgment call that belongs to a woman and her physician, weighing her specific infection burden, her overall health, and the stage of pregnancy, rather than a blanket rule applied without context.

What to Expect After Treatment

Albendazole does not work instantly, and expecting overnight relief sets an unrealistic bar. The drug begins interfering with the worm's metabolism within hours of absorption, but because adult worms are killed gradually through glycogen depletion rather than immediate destruction, most clinical guidance describes the process unfolding over several days. Expulsion of dead or dying worms in stool can continue for a few days after dosing, and it is not unusual for eggs to still be detectable in stool for a short period afterward, since the drug halts the worm's ability to survive and reproduce before it necessarily eliminates every trace of it from the gut.

Symptomatic improvement, particularly in cases involving anemia or gastrointestinal discomfort, tends to be gradual rather than immediate, tracking the body's own recovery of iron stores and gut lining health over weeks rather than days. For this reason, follow-up stool examination two to four weeks after treatment is the recommended way to confirm cure, rather than relying on how a patient feels. Anemia related to chronic hookworm infection may require iron supplementation alongside deworming, and correction of hemoglobin levels can take considerably longer than the antiparasitic treatment itself.

Side effects from a single or short course of albendazole are generally mild: some patients report headache, nausea, abdominal discomfort, or dizziness. These are usually transient. Longer courses at higher doses, as used for hydatid disease or neurocysticercosis, carry a different and more closely monitored safety profile, including the need for periodic liver enzyme and blood count checks, but this is not the regimen used for ordinary hookworm treatment.

Reinfection is the other reality worth naming plainly. Albendazole clears the current infection; it does not confer immunity. In areas where soil is contaminated with human waste and sanitation is limited, reinfection can occur within months. This is why public health programs pair mass drug administration with efforts to improve sanitation and hygiene, and why individuals and families in endemic or higher-risk settings should think of footwear, handwashing, and safe disposal of waste as part of the same protective picture as the medicine itself — personal responsibility and good stewardship working alongside sound pharmacology, not instead of it.

Talking to Your Doctor

Because hookworm shares symptoms with many other causes of fatigue and abdominal discomfort, a firm diagnosis by stool examination before treatment is the right starting point, not an assumption. Patients should feel free to ask their physician directly about the evidence behind the recommended regimen, whether a single dose or extended course fits their situation, and what follow-up testing will look like. Informed patients who understand both the strength and the limits of the evidence are in the best position to make sound decisions in partnership with their own doctor.

Key takeaway: Albendazole, most often as a single 400 mg dose, is a well-evidenced and generally well-tolerated treatment for hookworm, but full recovery depends on realistic expectations about timing, follow-up stool testing, and reducing the risk of reinfection.